The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)— approved in July in the US — lowered cholesterol in patients with familial hypercholesterolemia to levels “unreachable with statins” researchers said at the European Society of Cardiology meeting in London, UK.
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.
Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns